Key result
Endovascular therapy becomes the standard of care for LVO stroke despite ongoing access challenges.
Why the study?
Stroke remains a major cause of death and disability, and clinical pharmacology plays a key role in translating research into patient care and health policy.
Highlights the role of clinical pharmacology in stroke research and the emergence of endovascular therapy as the standard of care for ischemic stroke with large vessel occlusion.
Answers are grounded in this paper and cite their sources.
May inform multidisciplinary stroke trial design; leaves open optimal pharmacological adjuncts to endovascular therapy.
Keywords endovascular therapy, pharmacoepidemiology, platelets, secondary prevention, stroke Stroke is a major cause of death and disability, and the commonest form of acquired major physical disability in adult life, with up to one in six people suffering a stroke in their lifetime.The great ESCAPEa clinical pharmacologist's journey in stroke research outlines how clinical pharmacology, and stroke in particular, provides an example of the translational medicine continuum from bench to bedside to community to public policy.Clinical pharmacology is well positioned to have an ever-increasing role in the shaping of future health policies, particularly in the field of patient safety.Endovascular therapy will become the standard of care for treating ischaemic stroke with large vessel occlusion, although the provision of this therapy to all eligible patients will present a challenge to healthcare providers in the future.
No takes yet. Share an insight, caveat, or question.
David Williams (2016) conducted a review in Stroke. Endovascular therapy was evaluated. Endovascular therapy will become the standard of care for treating ischaemic stroke with large vessel occlusion, though providing it to all eligible patients will present a challenge.
Synapse has enriched 10 related papers. Consider them for comparative context: